Ultrafine-Particle Emission Factors as a Function of Vehicle Mode of Operation for LDVs Based on Near-Roadway Monitoring.

Environ Sci Technol

Department of Civil, Architectural, and Environmental Engineering, Illinois Institute of Technology, Chicago, Illinois 60616, United States.

Published: January 2016

This paper presents ultrafine-particle (UFP) emission factors (EFs) as a function of vehicle mode of operation (free flow and congestion) using (1) concurrent 5 min measurements of UFPs and carbon monoxide (CO) concentration, wind speed and direction, traffic volume and speed near a roadway that is restricted to light-duty vehicles (LDVs) and (2) inverse dispersion model calculations. Short-term measurements are required to characterize the highly variable and rapidly changing UFP concentration generated by vehicles. Under congestion conditions, the UFP vehicle EFs increased from 0.5 × 10(13) to 2 × 10(13) (particles km(-1) vehicle(-1)) when vehicle flow increased from 5500 to 7500 vehicles/h. For free-flow conditions, the EF is constant at 1.5 × 10(13) (particles km(-1) vehicle(-1)). The analysis is based on the assumption that air-quality models adequately describe the dilution process due to both traffic and atmospheric turbulence. The approach used to verify this assumption was to use an emission factor model to determine EFs for CO and then estimate dilution factors using measured CO concentrations. This procedure eliminates the need to rely only on air quality models to generate dilution factors. The EFs are suitable for fleet emissions under real-world traffic conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.est.5b03885DOI Listing

Publication Analysis

Top Keywords

emission factors
8
function vehicle
8
vehicle mode
8
mode operation
8
factors efs
8
1013 particles
8
particles km-1
8
km-1 vehicle-1
8
dilution factors
8
ultrafine-particle emission
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.

Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.

Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.

View Article and Find Full Text PDF

Background: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive emerging tool to modulate brain activities and functional connectivity in various neuropsychiatric disorders. rTMS combined with cognitive training (rTMS-COG) has been showing cognitive enhancing effects compared to those of placebo in mild Alzheimer's disease (AD) in some previous studies. However, there is not much research to conclude how much each rTMS or COG contributes to therapeutic cognitive effects.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Weill Cornell Medicine, New York City, NY, USA.

Background: Early detection of Alzheimer's disease (AD) can improve prognosis, given new anti-amyloid therapies. Both positron emission tomography (PET) and magnetic resonance (MR) imaging biomarkers are currently used (1). 48F-Fluorodeoxyglucose-PET (FDG-PET) can detect neurodegeneration-related hypometabolism but is costly and not easily accessible (2).

View Article and Find Full Text PDF

Background: Effect of dynamic lighting on sleep were studied since 1980's. Traditional light sources were used due to lack of advancement in technology and also researchers assumed illuminance as cause of melatonin suppression. This led researchers to use high illuminance to suppress melatonin at day time.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.

Background: Amyloid imaging biomarkers serve an increasingly important role in diagnosing Alzheimer's disease and determining eligibility for treatment with new disease-modifying therapies. Yet, psychological and behavioral reactions to receiving a biomarker informed diagnosis remain relatively unstudied, especially in diverse and underserved populations where the burden of disease is high and resources for support are often insufficient. We developed the Patient And family member Reactions to biomarker-informed ADRD DiagnosEs (PARADE) Study to address two key gaps in our understanding: 1) the range and trajectory of psychological and behavioral responses to a biomarker informed diagnosis and 2) the support needs of these individuals and their families.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!